Unichem Laboratories yesterday said it has received approval from the US health regulator to market Carbamazepine tablets, an anti-convulsant drug, in the American market. The company has received approval from the US Food and Drug Administration (FDA) to market its product in the strength of 200 mg, Unichem Laboratories said in a statement.
The drug maker’s product is the generic version of Novartis Pharma’s Tegretol tablets which is indicated for use as an anti-convulsant drug and in the treatment of the pain associated with trigeminal neuralgia.
The product will be produced at the company’s Goa plant, Unichem stated.
Edits by EP News Bureau
I love your great blog, thanks a lot and keep up the good work.
Hi, just wanted to say, I liked this post. It was practical.
Keep on posting!